PL362766A1 - Nowe pochodne imidazolu, sposób ich wytwarzania iich zastosowanie - Google Patents

Nowe pochodne imidazolu, sposób ich wytwarzania iich zastosowanie

Info

Publication number
PL362766A1
PL362766A1 PL01362766A PL36276601A PL362766A1 PL 362766 A1 PL362766 A1 PL 362766A1 PL 01362766 A PL01362766 A PL 01362766A PL 36276601 A PL36276601 A PL 36276601A PL 362766 A1 PL362766 A1 PL 362766A1
Authority
PL
Poland
Prior art keywords
compound
production method
imidazole derivatives
sub
mixture
Prior art date
Application number
PL01362766A
Other languages
English (en)
Other versions
PL204934B1 (pl
Inventor
Akihiro Tasaka
Takenori Hitaka
Nobuyuki Matsunaga
Masami Kusaka
Mari Adachi
Isao Aoki
Akio Ojida
Original Assignee
Takeda Pharmaceutical Company Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Company Limited filed Critical Takeda Pharmaceutical Company Limited
Publication of PL362766A1 publication Critical patent/PL362766A1/pl
Publication of PL204934B1 publication Critical patent/PL204934B1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

Przedmiotem niniejszego wynalazku jest związek wykazujący aktywność hamującą sterydową C<sub>17-29</sub>-liazę i przydatny do leczenia i zapobiegania nowotworom, takim jak rozrost stercz, rak piersi i tym podobne, oraz sposób wydajnego rozdzielania optycznie czynnej postaci tego związku z mieszaniny jego izomerów optycznych, związek o wzorze (I), w którym każdy symbol jest taki, jak zdefiniowano w opisie, jego sól lub przedlek, oraz sposób otrzymywania optycznie czynnego związku przez optyczne rozdzielanie mieszaniny izomerów optycznych z użyciem czynnika rozdzielającego, takiego jak monoanilid kwasu winowego i tym podobne.
PL362766A 2000-11-17 2001-11-16 Pochodne imidazolu i ich sole diastereomeryczne, kompozycje farmaceutyczne i środki do zmniejszania poziomu androgenu zawierające te pochodne oraz sposoby ich wytwarzania PL204934B1 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2000351780 2000-11-17
JP2001247618 2001-08-17
JP2001336880 2001-11-01
PCT/JP2001/010002 WO2002040484A2 (en) 2000-11-17 2001-11-16 Novel imidazole derivatives, production method thereof and use thereof

Publications (2)

Publication Number Publication Date
PL362766A1 true PL362766A1 (pl) 2004-11-02
PL204934B1 PL204934B1 (pl) 2010-02-26

Family

ID=27345219

Family Applications (1)

Application Number Title Priority Date Filing Date
PL362766A PL204934B1 (pl) 2000-11-17 2001-11-16 Pochodne imidazolu i ich sole diastereomeryczne, kompozycje farmaceutyczne i środki do zmniejszania poziomu androgenu zawierające te pochodne oraz sposoby ich wytwarzania

Country Status (26)

Country Link
US (1) US7141598B2 (pl)
EP (2) EP1681290B9 (pl)
JP (2) JP3753971B2 (pl)
KR (3) KR20080002929A (pl)
CN (3) CN1900079A (pl)
AR (1) AR034854A1 (pl)
AT (2) ATE533768T1 (pl)
AU (3) AU1429602A (pl)
BR (1) BR0115306B1 (pl)
CA (1) CA2429133C (pl)
CY (1) CY1105423T1 (pl)
DE (1) DE60119963T2 (pl)
DK (1) DK1334106T3 (pl)
ES (1) ES2260303T3 (pl)
HU (1) HU229408B1 (pl)
IL (2) IL155624A0 (pl)
MX (1) MXPA03004347A (pl)
MY (1) MY134929A (pl)
NO (1) NO326366B1 (pl)
NZ (1) NZ526387A (pl)
PE (1) PE20020596A1 (pl)
PL (1) PL204934B1 (pl)
PT (1) PT1334106E (pl)
SI (1) SI1334106T1 (pl)
TW (1) TWI306099B (pl)
WO (1) WO2002040484A2 (pl)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7662974B2 (en) * 2002-01-10 2010-02-16 Takeda Pharmaceutical Company Limited Process for producing fused imidazole compound, reformatsky reagent in stable form, and process for producing the same
JP4745616B2 (ja) * 2003-02-26 2011-08-10 武田薬品工業株式会社 安定化されたイミダゾール誘導体含有医薬組成物、イミダゾール誘導体の安定化方法
WO2004075890A1 (ja) * 2003-02-26 2004-09-10 Takeda Pharmaceutical Company 安定化されたイミダゾール誘導体含有医薬組成物、イミダゾ－ル誘導体の安定化方法
EP1607092A4 (en) * 2003-03-17 2010-12-15 Takeda Pharmaceutical COMPOSITIONS WITH CONTROLLED RELEASE
JP4837895B2 (ja) * 2003-03-17 2011-12-14 武田薬品工業株式会社 放出制御組成物
JP5070042B2 (ja) * 2004-05-03 2012-11-07 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 選択的アンドローゲン受容体モジュレーター（ｓａｒｍｓ）としての新規インドール化合物
JP5179174B2 (ja) * 2004-05-28 2013-04-10 ノバルティス ファーマ アーゲー アルドステロンシンターゼ阻害剤としてのテトラヒドロ−イミダゾ［１，５−ａ］ピリジン誘導体
EP1854463A4 (en) * 2005-03-03 2011-03-23 Takeda Pharmaceutical COMPOSITION WITH CONTROLLED RELEASE
GT200600381A (es) 2005-08-25 2007-03-28 Compuestos organicos
TW200804378A (en) * 2005-12-09 2008-01-16 Speedel Experimenta Ag Organic compounds
EP1991223B1 (en) * 2006-02-10 2010-07-14 Janssen Pharmaceutica, N.V. Novel imidazolopyrazole derivatives useful as selective androgen receptor modulators
AR060225A1 (es) * 2006-03-31 2008-06-04 Speedel Experimenta Ag Proceso para preparar 6,7- dihidro-5h-imidazo (1,5-a) piridin -8- ona
PE20090931A1 (es) * 2007-10-29 2009-08-03 Takeda Pharmaceutical Composicion farmaceutica que contiene un inhibidor de esteroide c17,20 liasa
TWI720517B (zh) * 2009-01-15 2021-03-01 美商英塞特公司 製造ｊａｋ抑制劑之方法及相關中間化合物
UY33740A (es) * 2010-11-18 2012-05-31 Takeda Pharmaceutical Método para tratar el cáncer de mama y cáncer de ovarios
AR085743A1 (es) 2011-04-01 2013-10-23 Takeda Pharmaceutical Preparacion solida
JP6082353B2 (ja) 2011-06-15 2017-02-15 武田薬品工業株式会社 イミダゾール誘導体の製造方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4728645A (en) * 1982-12-21 1988-03-01 Ciba-Geigy Corporation Substituted imidazo[1,5-A]pyridine derivatives and other substituted bicyclic derivatives, useful as aromatase inhibitors
NZ221729A (en) 1986-09-15 1989-07-27 Janssen Pharmaceutica Nv Imidazolyl methyl-substituted benzimidazole derivatives and pharmaceutical compositions
ZA882717B (en) 1987-04-22 1988-10-17 Merrell Dow Pharmaceuticals Inc. 17beta-(cyclopropylamino)-androst-5-eb-3beta-ol and related compounds useful as c17-20 lyase inhibitors
US5057521A (en) * 1988-10-26 1991-10-15 Ciba-Geigy Corporation Use of bicyclic imidazole compounds for the treatment of hyperaldosteronism
US4966898A (en) 1989-08-15 1990-10-30 Merrell Dow Pharmaceuticals Inc. 4-substituted 17β-(cyclopropylamino)androst-5-en-3β-ol and related compounds useful as C17-20 lyase inhibitors
CA2104234A1 (en) 1991-03-01 1993-07-22 Denis R. Mckay Powder coating method for producing circuit board laminae and the like
CA2127689A1 (en) * 1992-01-27 1993-08-05 Marcel A. C. Janssen Pyrroloimidazolyl and imidazopyridinyl substituted 1h-benzimidazole derivatives as aromatase inhibitors
US5457102A (en) * 1994-07-07 1995-10-10 Janssen Pharmaceutica, N.V. Pyrroloimidazolyl and imidazopyridinyl substituted 1H-benzimidazole derivatives
CA2132449C (en) 1992-03-31 2002-09-10 Susan E. Barrie 17 - substituted steroids useful in cancer treatment
GB9310635D0 (en) 1993-05-21 1993-07-07 Glaxo Group Ltd Chemical compounds
WO1995009157A1 (en) 1993-09-30 1995-04-06 Yamanouchi Pharmaceutical Co., Ltd. Azole derivative and pharmaceutical composition thereof
AU3846395A (en) 1994-11-07 1996-05-31 Janssen Pharmaceutica N.V. Compositions comprising carbazoles and cyclodextrins
WO1997000257A1 (en) 1995-06-14 1997-01-03 Yamanouchi Pharmaceutical Co., Ltd. Fused imidazole derivatives and medicinal composition thereof
WO1998037070A1 (en) 1997-02-21 1998-08-27 Takeda Chemical Industries, Ltd. Fused ring compounds, process for producing the same and use thereof
DE69823222T2 (de) 1997-10-02 2005-04-14 Daiichi Pharmaceutical Co., Ltd. Dihydronaphthalinderivate und verfahren zur herstellung derselben
EP1073640B1 (en) 1998-04-23 2005-04-13 Takeda Pharmaceutical Company Limited Naphthalene derivatives, their production and use
PE20010781A1 (es) * 1999-10-22 2001-08-08 Takeda Chemical Industries Ltd Compuestos 1-(1h-imidazol-4-il)-1-(naftil-2-sustituido)etanol, su produccion y utilizacion

Also Published As

Publication number Publication date
TWI306099B (en) 2009-02-11
PL204934B1 (pl) 2010-02-26
US7141598B2 (en) 2006-11-28
ATE533768T1 (de) 2011-12-15
NO326366B1 (no) 2008-11-17
JP2006045239A (ja) 2006-02-16
CN100572363C (zh) 2009-12-23
EP1334106B1 (en) 2006-05-24
HK1056168A1 (en) 2004-02-06
CN1329394C (zh) 2007-08-01
AR034854A1 (es) 2004-03-24
AU2002214296C1 (en) 2006-04-13
EP1681290B9 (en) 2013-06-19
CN1900079A (zh) 2007-01-24
SI1334106T1 (sl) 2006-10-31
JP2003201282A (ja) 2003-07-18
JP4427496B2 (ja) 2010-03-10
DE60119963T2 (de) 2006-10-05
BR0115306B1 (pt) 2013-12-24
HUP0400549A3 (en) 2004-09-28
AU1429602A (en) 2002-05-27
ES2260303T3 (es) 2006-11-01
EP1681290B1 (en) 2011-11-16
KR20050105287A (ko) 2005-11-03
CN1680336A (zh) 2005-10-12
EP1681290A2 (en) 2006-07-19
CY1105423T1 (el) 2010-04-28
US20040033935A1 (en) 2004-02-19
CN1474819A (zh) 2004-02-11
MXPA03004347A (es) 2004-05-04
DK1334106T3 (da) 2006-09-18
KR100725442B1 (ko) 2007-06-07
WO2002040484A2 (en) 2002-05-23
PE20020596A1 (es) 2002-08-13
AU2005225035A1 (en) 2005-11-10
CA2429133A1 (en) 2002-05-23
JP3753971B2 (ja) 2006-03-08
WO2002040484A3 (en) 2002-09-26
IL155624A (en) 2006-12-31
HUP0400549A2 (hu) 2004-06-28
ATE327237T1 (de) 2006-06-15
AU2002214296B2 (en) 2005-09-29
BR0115306A (pt) 2004-02-10
KR20030048156A (ko) 2003-06-18
KR100809899B1 (ko) 2008-03-10
CA2429133C (en) 2009-08-18
NO20032234L (no) 2003-07-16
NO20032234D0 (no) 2003-05-16
HU229408B1 (hu) 2013-12-30
EP1681290A3 (en) 2006-07-26
KR20080002929A (ko) 2008-01-04
AU2005225035B2 (en) 2007-02-22
IL155624A0 (en) 2003-11-23
MY134929A (en) 2008-01-31
NZ526387A (en) 2004-02-27
EP1334106A2 (en) 2003-08-13
PT1334106E (pt) 2006-08-31
DE60119963D1 (de) 2006-06-29

Similar Documents

Publication Publication Date Title
PL362766A1 (pl) Nowe pochodne imidazolu, sposób ich wytwarzania iich zastosowanie
CO5650246A2 (es) Derivados de indazolil(indolil)maleimida sustituidos como inhibidores de cinasa
ATE363473T1 (de) Substituierte pyrazoloverbindungen zur behandlung von entzündungen
MY134783A (en) Rho-kinase inhibitors
MY142915A (en) Rho-kinase inhibitors
CY1107747T1 (el) Υποκατεστημενα τετρακυκλικα παραγωγα πυρρολοκινολονης χρησιμα ως αναστολεις της φωσφοδιεστερασης
NO20020214L (no) Substituerte oksoazaheterocyklylforbindelser
ATE433447T1 (de) Pyrimiidinverbindungen
TNSN06074A1 (en) Pyrimidine derivatives for the treatment of abnormal cell growth
ATE296826T1 (de) Pyrazolo(1,5)pyridinderivate
YU37904A (sh) Benzimidazoli kao korisni inhibitori proteinske kinaze
MX2023009379A (es) Derivados de tetrahidroazepina biciclicos para el tratamiento del cancer.
ES2243579T3 (es) Derivados de pirazolopirideno.
DE60228098D1 (de) Pyridin-substituierte furanderivate als raf-kinase inhibitoren
WO2004084812A3 (en) Tamandarin analogs and fragments thereof and methods of making and using
NO20043016L (no) 6-aminomorfinan-derivater, fremgangsmate for fremstilling og anvendelse derav
DK1056704T3 (da) Antitumormidler
NO20020161L (no) Vitamin D3-analoger
PT1606288E (pt) Derivados de benzenossulfonamida, processo para a sua preparação e a sua utilização para tratamento da dor
MY138466A (en) Aminoalkoxyndoles as 5-ht6-receptor ligands for the treatment of cns-disorders
DE60312029D1 (de) Verfahren zur herstellung c-7 substituierter 5-androstene
AU2003300385A8 (en) Anticancer compounds
ATE419242T1 (de) Pyrrolidinylharnstoffderivate als angiogeneseinhibitoren
EP1511472A4 (en) USEFUL COMPOUNDS FOR THE TREATMENT OF ANTHRAX AND INHIBITION OF THE LETAL FACTOR
BR0318521A (pt) arilindenopiridinas e arilindenopirimidinas e métodos terapêuticos e profiláticos relacionados